• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Clinical Experiences With Bimekizumab


Experts in dermatology discuss the use of bimekizumab in clinical practice for plaque psoriasis as well as its off-label use.

This is a video synopsis of a discussion involving Mark Lebwohl, MD, Dean for Clinical Therapeutics and Chairman Emeritus of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in Manhattan, New York, and Saakshi Khattri, MD, a board-certified dermatologist, rheumatologist, and internist at the same institution.

The panelists reflect on the introduction of bimekizumab as a treatment for psoriasis, recounting early patient responses indicating rapid and significant improvement in psoriatic symptoms, even within the first week of treatment initiation. Dr. Lebwohl underscores the drug's efficacy in psoriatic arthritis patients, noting instances where bimekizumab led to remarkable improvements, surpassing previous treatment failures.

Despite initial concerns regarding combination therapy, including IL-17 blockers and Janus kinase inhibitors, anecdotal evidence suggests that bimekizumab can effectively address both skin and joint symptoms in psoriatic patients. Dr. Khattri shares her off-label use of bimekizumab in patients with psoriatic arthritis outside the US, highlighting its efficacy in improving mobility and reducing stiffness.

The discussion delves into bimekizumab's mechanism of action, emphasizing its unique ability to block both IL-17A and IL-17F, which are overexpressed in psoriatic patients. Head-to-head comparisons with other IL-17 blockers demonstrate bimekizumab's superiority, particularly in achieving PASI 100 response rates.

Dr. Lebwohl and Dr. Khattri agree that bimekizumab represents a significant advancement in psoriasis treatment, offering patients a higher standard of care with the potential for greater symptom relief and improved quality of life. They anticipate continued exploration of bimekizumab's efficacy and its role in managing psoriatic disease across diverse patient populations.

Video synopsis is AI-generated and reviewed by Dermatology Times® editorial staff.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.